MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Acelyrin, Inc. (NASDAQ: SLRN)*
Organization & Developments: Acelryin
Parents
Acelyrin, Inc. (NASDAQ: SLRN)*
Children
*Developing izokibep, an antibody mimetic interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of monoclonal antibodies.
*The small size of izokibep – about one tenth the size of a monoclonal antibody – enables its potential to reach targeted tissues that may otherwise be inaccessible to the much larger monoclonal antibodies.
*With high potency and small molecular size, izokibep can reach high drug exposure levels through a single, subcutaneous injection that monoclonal antibodies require IV administration to achieve.
2023: Acelyrin has a late-stage drug in the form of izokibep, a subcutaneous injectable meant to compete with blockbuster anti-inflammatory medicines from Novartis and Eli Lilly
2024: Acelyrin loses interest in izokibep, lays off 3rd of staff to focus on looming fight for Tepezza's crown
2024: Acelyrin: Abandoned Programs Do Not Give Confidence_seekingalpha.com
2024: Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis
2024: Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch_ seekingalpha.com
2025: Acelyrin: Potential Buyout Led By Concentra Biosciences
Jumps
Finance & Acquisitions: Acelryin
Key People: Acelryin